A 6 months, multicenter study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis To evaluate the effect of an individualized patient support program vs. a standard patient support program on treatment satisfaction, measured by a treatment satisfaction questionnaire (TSQM-9) in Fin...

• Country None
• organs None
• Specialty None

Study to assess the effects of a 3 week therapy each with QVA149 versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe COPD Primary objective:  To demonstrate that QVA149 (110/50 μg q.d.) is superior compared to placebo on peak inspiratory capacity (IC) after 21 days of treatment in patients with moderate to severe COPD....

• Country None
• organs None
• Specialty None

An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to a 4 week therapy with candesartan 32 mg plus hydrochlorothiazide 25 mg To demonstrate that 4 weeks of treatment with aliskiren 300mg plus hydrochlorothiazide 25mg in combination provide an additional mean sitting diastolic blood pressure reduction in hypertensive patient...

• Country None
• organs None
• Specialty None

Exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis To evaluate flow mediated dilation (FMD) by Doppler ultrasound at week 12 in subjects in treatment arm A (300 mg Secukinumab) compared to the pooled group of patients in treatment arms C and D (placeb...

• Country None
• organs None
• Specialty None

Study in patients with moderate to severe psoriasis with secukinumab To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS (the worst itching within a recall period of 24 hours as part of the Patients Global Assessment ...

• Country None
• organs None
• Specialty None

An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors To assess response in patients with MPNST treated with Imatinib. Response is defined as at least stable disease according to RECIST criteria.

• Country None
• organs None
• Specialty None

An open-label clinical trial that evaluates the lung clearance index in cystic fibrosis patients ≥ 6 years of age, chronically infected with Pseudomonas aeruginosa To assess the change of LCI after 4 weeks following onset of study drug inhalation versus Baseline

• Country None
• organs None
• Specialty None

A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrate 200 mg on HDL-C in comparison to the combination of simvastatin 20 mg and ezetimibe 10 mg in patients with metabolic syndrome To confirm that the combination of fluvastatin 80 mg extended release (ER) and fenofibrate 200 mg has superior efficacy in increasing HDL-C compared with the combination of simvastatin 20 mg and ezeti...

• Country None
• organs None
• Specialty None

A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression To evaluate the safety and tolerability profile of the combination therapy of an antidepressant type SSRI or SNRI with oral fingolimod with respect to adverse events and laboratory parameters

• Country None
• organs None
• Specialty None

A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment in patients with hormone-refractory prostate cancer To investigate the effect of a treatment with Imatinib mesylate (Glivec®), Pioglitazone (Actos®), Dexamethasone (Fortecortin®) and Etoricoxib (Arcoxia®) in combination with metronomic chemotherapy (Tr...

• Country None
• organs None
• Specialty None